About: Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: A multi-center observational study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: A multi-center observational study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: A multi-center observational study
Creator	Walker, David Ma, Boston Ahn, Jaeil Bednarz, Urszula Calise, Arthur Capra, Samuel Ccrp, B Cota, M Cunningham, Frank Eagan, Michael Goldberg, Stuart Goy, Andre Hansen, Eric Ip, Andrew Marafelias, Michael Mastrokyriakos, Paul Mathura, Shivam Mojares, Greggory Pecora, Andrew Ponce, Marie Prasad, Rajiv Pulver, Bradley Ruocco, Dominic Sawczuk, Ihor Sinclaire, Brittany Sweeney, Robert Underwood, Joseph Zhou, Yizhao Ziontz, Kristy
Source	MedRxiv
abstract	Background: Hydroxychloroquine has not been associated with improved survival among hospitalized COVID-19 patients in the majority of observational studies and similarly was not identified as an effective prophylaxis following exposure in a prospective randomized trial. We aimed to explore the role of hydroxychloroquine therapy in mildly symptomatic patients diagnosed in the outpatient setting. Methods: We examined the association between outpatient hydroxychloroquine exposure and the subsequent progression of disease among mildly symptomatic non-hospitalized patients with documented SARS-CoV-2 infection. The primary outcome assessed was requirement of hospitalization. Data was obtained from a retrospective review of electronic health records within a New Jersey USA multi-hospital network. We compared outcomes in patients who received hydroxychloroquine with those who did not applying a multivariable logistic model with propensity matching. Results: Among 1274 outpatients with documented SARS-CoV-2 infection 7.6% were prescribed hydroxychloroquine. In a 1067 patient propensity matched cohort, 21.6% with outpatient exposure to hydroxychloroquine were hospitalized, and 31.4% without exposure were hospitalized. In the primary multivariable logistic regression analysis with propensity matching there was an association between exposure to hydroxychloroquine and a decreased rate of hospitalization from COVID-19 (OR 0.53; 95% CI, 0.29, 0.95). Sensitivity analyses revealed similar associations. QTc prolongation events occurred in 2% of patients prescribed hydroxychloroquine with no reported arrhythmia events among those with data available. Conclusions: In this retrospective observational study of SARS-CoV-2 infected non-hospitalized patients hydroxychloroquine exposure was associated with a decreased rate of subsequent hospitalization. Additional exploration of hydroxychloroquine in this mildly symptomatic outpatient population is warranted.
has issue date	2020-08-25(xsd:dateTime)
bibo:doi	10.1101/2020.08.20.20178772
has license	medrxiv
sha1sum (hex)	d97335243dbd0396a9a03af9aee2d476bc9a33a6
schema:url	https://doi.org/10.1101/2020.08.20.20178772
resource representing a document's title	Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: A multi-center observational study
resource representing a document's body	covid:d97335243dbd0396a9a03af9aee2d476bc9a33a6#body_text
is schema:about of	named entity 'observational study' named entity 'SUMMARY' named entity 'DISCUSSION' covid:arg/d97335243dbd0396a9a03af9aee2d476bc9a33a6 named entity 'patients' named entity 'clinical trial' named entity 'arrhythmias' named entity 'outpatient setting' named entity 'hydroxychloroquine' named entity 'observational study' named entity 'hydroxychloroquine' named entity 'stepwise selection' named entity 'preprint' named entity 'viral load' named entity 'viral load' named entity 'covariate' named entity 'peer review' named entity 'hydroxychloroquine' named entity 'peer review' named entity 'preprint' named entity 'COVID-19' named entity 'randomized trial' named entity 'preprint' named entity 'Hackensack Meridian Health' named entity 'COVID-19 pandemic' named entity 'COVID' named entity 'shortness of breath' named entity 'logistic regression' named entity 'Arrhythmia' named entity 'arrhythmia' named entity 'cohort study' named entity 'propensity scores' named entity 'preprint' named entity 'antimalarial agent' named entity 'Centers for Disease Control and Prevention' named entity 'missing data' named entity 'preprint' named entity 'preprint' named entity 'hydroxychloroquine' named entity 'preprint' named entity 'preprint' named entity 'hydroxychloroquine' named entity 'COVID' named entity '95% CI' named entity 'hydroxychloroquine' named entity 'median test' named entity 'asymptomatic' named entity 'outpatient setting' named entity 'preprint' named entity 'hydroxychloroquine' named entity 'infection' named entity 'zinc' named entity 'medRxiv' named entity 'QTc prolongation' named entity 'hydroxychloroquine' named entity 'hydroxychloroquine' named entity 'preprint'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software